CARDIOLOGY INSIGHTS
The Inherited Risk Factor
Lipoprotein(a): Who Should Test, What High Results Mean, and What to Do About It
SONAL CHANDRA, MD
Lipoprotein(a), or Lp(a), is one of the most clinically significant cardiovascular risk factors most people have never had measured. It is genetically determined, present from birth, and largely unresponsive to diet and lifestyle. Elevated Lp(a) affects roughly one in five people globally and the majority of them, unfortunately, have never been told. That is not an acceptable gap in preventive care.
What Lp(a) Is and Why It Matters
Lp(a) is a lipoprotein particle structurally similar to LDL but with an additional protein named apolipoprotein(a) attached. That structural addition makes it more likely to form plaques than standard LDL: it promotes plaque formation, has pro-inflammatory and pro-clotting properties, and has been independently associated with coronary artery disease, aortic stenosis, and stroke events. Critically, it contributes to cardiovascular risk in addition to and independent of LDL — meaning a patient with well-managed LDL and elevated Lp(a) still carries elevated risk.
Who Should Test — and Why Many Experts Recommend at Least Once
Current guidelines from the European Society of Cardiology, the European Atherosclerosis Society, and an increasing number of North American consensus statements recommend that every adult have Lp(a) measured at least once. The rationale is straightforward: it is genetically fixed, it cannot be determined or calculated from other labs and it is inexpensive to measure. Knowing it changes how aggressively other modifiable risk factors should be managed. Priority patients for testing include anyone with a personal or family history of premature cardiovascular disease, anyone with a first-degree relative with known elevated Lp(a), anyone with aortic stenosis without conventional risk factors, and anyone in whom the decision to intensify or initiate lipid therapy remains uncertain despite standard testing.
What “High” Means — mg/dL vs. nmol/L
Lp(a) can be reported in two units, and the thresholds differ. In mg/dL, a level above 30 mg/dL is considered elevated and above 50 mg/dL is high risk — the threshold used in most major trials and guidelines. In nmol/L (the more precise unit, less affected by particle size variation), the corresponding high-risk threshold is above 125 nmol/L. When interpreting results, always confirm which unit was used. A result of 50 in nmol/L is not the same clinical finding as 50 in mg/dL, and the distinction has direct implications for how aggressively the rest of the risk profile should be managed.
Lp(a) and Menopause — A Clinically Important Connection
For women, Lp(a) has an additional dimension that is rarely discussed: the menopausal transition appears to raise it. Because estrogen directly suppresses the gene responsible for Lp(a) production (the LPA gene), falling estrogen levels during perimenopause and menopause remove that suppressive effect — and Lp(a) rises. A 2022 systematic review and meta-analysis of 15 studies, covering nearly 13,000 women, found that postmenopausal women had meaningfully higher Lp(a) concentrations than their premenopausal counterparts. The difference averaged approximately 3.8 mg/dL modest in absolute terms but clinically significant when added to an already elevated baseline.
The implication is direct: a woman who had Lp(a) tested in her thirties and was told her level was borderline may now be meaningfully higher without knowing it. The 2024 National Lipid Association update explicitly recognizes major hormonal shifts as a reason Lp(a) may change over time and flags this as a situation where re-testing may be warranted. Hormone replacement therapy using oral estrogen has been shown to lower Lp(a) by 20 to 25 percent in multiple randomized trials, though HRT is not currently recommended as a strategy specifically to manage Lp(a).
The cardioprotective effects of HRT on Lp(a) are real, but the decision to use HRT must be individualized on the basis of the full risk picture and not driven by Lp(a) alone.
When Lp(a) Is Elevated: Tests That Become Important
An elevated Lp(a) does not necessarily cause harm in isolation; it amplifies the risk carried by everything else in your cardiovascular profile.
The following tests become especially important once an elevated Lp(a) is confirmed.
ApoB and Full Lipid Panel
ApoB measures the total number of atherogenic particles in circulation and is a better predictor of atherosclerotic risk than LDL-C alone. In the presence of high Lp(a), ApoB becomes even more essential because Lp(a) itself carries one ApoB molecule per particle contributing to total atherogenic burden in a way that standard cholesterol panels significantly underestimate.
Coronary Artery Calcium (CAC) Score
A CAC scan directly quantifies calcified plaque in the coronary arteries. For a patient with elevated Lp(a), it answers the most important practical question: has the elevated Lp(a) already caused measurable arterial damage? A high CAC score in the presence of elevated Lp(a) accelerates the urgency of every other intervention. A score of zero is reassuring but does not eliminate risk — it establishes a baseline from which to monitor.
High-Sensitivity CRP (hs-CRP)
Lp(a) drives inflammation within arterial plaques, and hs-CRP reflects systemic inflammatory burden. An elevated hs-CRP alongside high Lp(a) signals that the inflammatory pathway is active which has implications for both risk assessment and the potential role of anti-inflammatory strategies.
Fasting Glucose, HbA1c, and Insulin
Metabolic health profoundly modifies cardiovascular risk. Insulin resistance and prediabetes compound the risk from Lp(a) and are frequently under-detected on standard panels. A full metabolic assessment including fasting insulin and HbA1c completes the picture.
Blood Pressure and Resting Heart Rate
Hypertension in the presence of elevated Lp(a) creates a particularly unfavorable vascular environment. Endothelial function, already challenged by Lp(a)’s pro-inflammatory and pro-thrombotic effects, deteriorates further under sustained pressure load. Tight blood pressure control becomes a higher priority.
Family Member Screening
Because Lp(a) is 70 to 90 percent genetically determined, an elevated result in one family member is a direct signal that first-degree relatives should be tested. This is not a reactive recommendation — it is how the most impactful prevention conversations get started in families who did not know they were at risk.
What Lifestyle Can and Cannot Do
It is important to be clear about what lifestyle changes can realistically accomplish when Lp(a) is elevated, because misleading reassurances do no one any favors.
Lp(a) itself is largely unresponsive to diet, exercise, weight loss, or alcohol reduction. It is set predominantly by genetics, and no lifestyle intervention has been shown to lower it meaningfully. This is not an invitation to abandon healthy habits — it is the opposite. Because you cannot change the Lp(a) level directly, every modifiable risk factor surrounding it becomes more important, not less.
Regular aerobic and resistance exercise improves endothelial function, lowers LDL particle number, reduces insulin resistance, and decreases systemic inflammation: all of which partially offset the atherogenic environment that elevated Lp(a) creates.
An anti-inflammatory dietary pattern (rich in vegetables, fiber, healthy fats, and adequate protein, with minimal ultra-processed food and refined carbohydrates) reduces the inflammatory burden that Lp(a) amplifies.
Eliminating smoking is non-negotiable: the combination of Lp(a) and tobacco creates a vascular risk profile that is substantially greater than either alone. Optimizing sleep, managing chronic stress, and reducing visceral fat all reduce the inflammatory and metabolic load that elevated Lp(a) exploits.
What Actually Lowers Risk When Lp(a) Is High
and what is on the horizon
PCSK9 Inhibitors
Currently the most effective available option for directly lowering Lp(a). Evolocumab and alirocumab reduce Lp(a) by approximately 23 to 27 percent while simultaneously lowering LDL by 50 to 60 percent. For patients with elevated Lp(a) who also need LDL lowering (which is most of them) a PCSK9 inhibitor addresses both simultaneously and is often the preferred pharmacological choice.
Aspirin: The Evidence Is Emerging, Not Yet Definitive
Because Lp(a) promotes platelet activation and impairs fibrinolysis, aspirin’s antiplatelet mechanism has biological plausibility as a targeted therapy. Multiple observational and genetic studies have suggested a particular benefit of aspirin in individuals with elevated Lp(a).
A 2024 study using the Multi-Ethnic Study of Atherosclerosis (MESA) cohort found regular aspirin use was associated with a 52 percent lower risk of cardiovascular mortality in individuals with Lp(a) ≥ 50 mg/dL. However, the 2022 European Atherosclerosis Society consensus statement and the 2024 ACC/AHA guidelines both conclude that current data do not yet support a universal recommendation for aspirin based on Lp(a) level alone, and that a randomized controlled trial is still needed.
The 2024 National Lipid Association update describes aspirin as worthy of consideration using a patient-centered approach in those with elevated Lp(a) and low bleeding risk.
RNA-Targeted Therapies: The Near Future
Several RNA-based therapies specifically designed to suppress Lp(a) production in the liver are in late-stage Phase 3 clinical trials. Pelacarsen, olpasiran, and zerlasiran have each demonstrated the ability to lower Lp(a) by 70 to 90 percent in early trials. These represent the most significant development in Lp(a) treatment in decades, and results from outcomes trials are anticipated within the next few years.
You cannot change your Lp(a).
You can change how precisely and aggressively everything around it is managed and that difference is measurable.